mcas and semaglutide GLP-1RAs Show Therapeutic Potential in Mast Cell-Driven Diseases Mast Cell Activation Syndrome (MCAS)

If you look closely at the bottom panels of the 2 graphs above for loss of body weight, the participants in the new trial had 40% less weight loss than in the previous trial of obese, non-diabetic participants

Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases

Both compounds work identically in male and female research modelsGH and ghrelin receptor physiology does not differ meaningfully by sex

Whether investigating telomerase activity, circadian rhythm regulation, or cellular health markers, epithalon continues to reveal new insights into biological processes